Survodutide (BI 456906)

Structure: 39-amino-acid synthetic peptide with dual receptor activity at glucagon and GLP-1 receptors. Lipid acylation enables albumin binding for once-weekly dosing.

Status: Investigational / pipeline (as of 2025).

• Not approved by FDA, EMA, TGA, or any major regulator at the time of writing.
• Phase 2 obesity trial published 2024 (le Roux et al., Lancet Diabetes & Endocrinology) showed up to ~19% body weight loss at 46 weeks.
• Phase 2 MASH trial published 2024 (Sanyal et al., NEJM) showed substantial reduction in hepatic fat and resolution of MASH histology.
• Multiple Phase 3 trials ongoing. Earliest possible approval in major markets is unlikely before late 2026.

Dosage (Phase 2 trial range):

• Titration: 0.3mg/week, escalating monthly through 0.9, 1.8, 2.7, 3.6, 4.8mg/week
• Maintenance: doses up to 4.8mg/week explored in obesity Phase 2

Administration:

• Once-weekly SubQ injection
• Slow titration is essential; rapid escalation produces severe nausea

Key Notes:

• The glucagon component is the differentiator from pure GLP-1 (semaglutide) and GLP-1/GIP dual agonists (tirzepatide). Glucagon increases hepatic glucose output and energy expenditure; the net glycaemic effect remains beneficial because the GLP-1 component drives insulin secretion.
• Hepatic fat reduction is the strongest emerging signal. Survodutide may become a leading agent for MASH (formerly NASH) regardless of weight indication.
• Bodybuilding relevance: theoretically muscle-sparing compared to pure GLP-1 agonists because the glucagon component preserves resting energy expenditure, reducing the metabolic adaptation that drives muscle loss in caloric deficit. Real-world bodybuilding data does not yet exist.
• Grey market sourcing exists ahead of approval. Product purity from research peptide vendors is highly variable; counterfeit and underdosed product is common. Self-titration without a clinical sponsor is high-risk.
• Pancreatitis, gallbladder disease, and the medullary thyroid carcinoma class warning apply by extrapolation from the GLP-1 class.
• Monitor: fasting glucose, HbA1c, lipid panel, liver enzymes (ALT, AST, GGT), amylase / lipase, heart rate, blood pressure.

References:

• le Roux, C. W., Steen, O., Lucas, K. J., Startseva, E., Unseld, A., Hennige, A. M. (2024). Glucagon and GLP-1 receptor dual agonist survodutide for obesity: a randomised, double-blind, placebo-controlled, dose-finding phase 2 trial. The Lancet Diabetes & Endocrinology, 12(3), 162-173. DOI: 10.1016/S2213-8587(23)00356-X
• Sanyal, A. J., Bedossa, P., Fraessdorf, M., Neff, G. W., Lawitz, E., Bugianesi, E., Anstee, Q. M., Hussain, S. A., Newsome, P. N., Ratziu, V., Hosseini-Tabatabaei, A., Schattenberg, J. M., Noureddin, M., Alkhouri, N., Younes, R., Albillos, A., Garcia-Rosado, A., et al. (2024). A phase 2 randomized trial of survodutide in MASH and fibrosis. New England Journal of Medicine, 391(4), 311-319. DOI: 10.1056/NEJMoa2401755
• Zimmermann, T., Thomas, L., Baader-Pagler, T., Haebel, P., Simon, E., Reindl, W., Bajrami, B., Rist, W., Uphues, I., Drucker, D. J., Klein, H., Santhanam, R., Hennige, A. M., Hamilton, B., & Augustin, R. (2022). BI 456906: discovery and preclinical pharmacology of a novel GCGR/GLP-1R dual agonist with robust anti-obesity efficacy. Molecular Metabolism, 66, 101633. DOI: 10.1016/j.molmet.2022.101633